Subsequent Events (Details) - USD ($)							1 Months Ended	9 Months Ended
	Nov. 06, 2020	Oct. 09, 2020	Oct. 08, 2020	Oct. 07, 2020	Oct. 06, 2020	Oct. 05, 2020	Sep. 30, 2020	Sep. 30, 2020	Jul. 31, 2021	Feb. 28, 2021	Dec. 31, 2019	Aug. 28, 2018
Phase 3 Clinical Trial for Cancer-therapy related Diarrhea
Amount of shares issued								$ 668,000
Preferred Stock Exchange
Convertible warrants												9,580
Warrants and Rights Outstanding							$ 126,000	126,000			$ 3,000
Fee Settlement Agreement
Convertible warrants												9,580
Fourth Amendment to Accounts Receivable Purchase Agreement With Oasis Capital, LLC
Accounts receivable							1,505,000	$ 1,505,000			$ 1,692,000
Iliad | Series C perpetual preferred stock
Phase 3 Clinical Trial for Cancer-therapy related Diarrhea
Amount of shares issued							$ 842,500
Subsequent event | Exchange Agreement with Iliad
3(a)(9) Exchanges
Shares issued on conversion			250,000
Preferred Stock Exchange
Shares issued on conversion			250,000
Subsequent event | Fee Settlement Agreement
Phase 3 Clinical Trial for Cancer-therapy related Diarrhea
Shares issued (in shares)				2,000,000
Preferred Stock Exchange
Convertible warrants				6,218,954
Fee Settlement Agreement
Shares issued (in shares)				2,000,000
Convertible warrants				6,218,954
Trial delay fee event of failure of initiation of phase 2 study				$ 2,500,000
Subsequent event | Royalty Purchase Agreement
Royalty Transaction
Payment of royalty			$ 12,000,000
Aggregate purchase price			$ 6,000,000
Percentage of interest on royalty			10.00%
Minimum royalty payable			$ 250,000
Percentage of worldwide revenues			10.00%
Minimum volume weighted average price of stock			$ 0.3035
Increase in royalty repayment amount			$ 6,000,000
Additional royalty financings committed									$ 6,000,000	$ 5,000,000
Percentage of increase in royalty			15.00%
Subsequent event | Mytesi | Royalty Purchase Agreement
Royalty Transaction
Percentage of net sales of Mytesi			10.00%
Subsequent event | Beginning on October 9, 2021 | Royalty Purchase Agreement
Royalty Transaction
Minimum royalty payable			$ 400,000
Subsequent event | Beginning on April 9, 2022 | Royalty Purchase Agreement
Royalty Transaction
Minimum royalty payable			600,000
Subsequent event | Beginning on October 9, 2022 | Royalty Purchase Agreement
Royalty Transaction
Minimum royalty payable			$ 750,000
Subsequent event | Pre-funded Warrants | Exchange Agreement with Iliad
3(a)(9) Exchanges
Shares issued on conversion	6,700,000
Preferred Stock Exchange
Shares issued on conversion	6,700,000
Convertible warrants			7,057,692
Number of warrants converted for each share			1
Exercise price (in dollars per share)			$ 0.0001
Warrants and Rights Outstanding	$ 1,000
Fee Settlement Agreement
Convertible warrants			7,057,692
Subsequent event | Series C perpetual preferred stock | Exchange Agreement with Iliad
3(a)(9) Exchanges
Shares converted			285,000
Preferred Stock Exchange
Shares converted			285,000
Subsequent event | Series B-2 convertible preferred stock
3(a)(9) Exchanges
Shares issued on conversion					500,186
Shares converted					975
Preferred Stock Exchange
Shares converted					975
Shares issued on conversion					500,186
Subsequent event | CVP Exchange Note 1
3(a)(9) Exchanges
Shares issued on conversion					3,350,000
Reduction in outstanding balance of notes					$ 1,000,000
Preferred Stock Exchange
Shares issued on conversion					3,350,000
Subsequent event | Oasis Secured Note Tranche 5
Fourth Amendment to Accounts Receivable Purchase Agreement With Oasis Capital, LLC
Fee to be received (percentage)		5.45%
Subsequent event | Oasis Secured Note Tranche 5 | Oasis Capital
Fourth Amendment to Accounts Receivable Purchase Agreement With Oasis Capital, LLC
Cash proceeds		$ 900,097
Accounts receivable		900,000
Accounts receivable gross		2,118,000
Accumulated chargebacks and discounts on accounts receivable		1,218,000
Threshold price		$ 1,015,000
Number of days within which to return excess collection amount		5 days
Transaction fee		$ 5,000
Agreement term		1 year
Agreement renewal term		1 year
Non renewal notice period before expiration		30 years
Notice period for termination Of agreement		60 days
Subsequent event | Oasis Secured Note Tranche 5 | Oasis Capital | Maximum
Fourth Amendment to Accounts Receivable Purchase Agreement With Oasis Capital, LLC
Additional transaction fee		$ 5,000
Subsequent event | Integrium, LLC | Napo | Master Services Agreement
Phase 3 Clinical Trial for Cancer-therapy related Diarrhea
Clinical trial expenses payable						$ 12,400,000
Subsequent event | PoC Capital, LLC | Stock Plan Agreement with Poc LLc
Phase 3 Clinical Trial for Cancer-therapy related Diarrhea
Shares issued (in shares)					1,333,333
Common stock par value (in dollars per share)					$ 0.0001
Share issue price (in dollars per share)					$ 0.30
Fee Settlement Agreement
Shares issued (in shares)					1,333,333
Subsequent event | PoC Capital, LLC | Napo | Stock Plan Agreement with Poc LLc
Phase 3 Clinical Trial for Cancer-therapy related Diarrhea
Amount of shares issued					$ 400,000
Subsequent event | At The Market Offering | Maximum
Subsequent Events.
Percentage of commission on gross sales proceeds						3.00%
Sale of worth of shares						$ 7,000,000